Learn from the pioneers of immunotherapy
Engineering Smarter Adoptive Cell Therapies
Cell-Mediated Therapies for Infectious Disease Summit
Development of next-generation TCR-T products
T-cell trial will include controversial chemo agent fludarabine.
Biotech says “robust” clinical response in early stage trial.
As immuno-oncology increasingly involves more than one agent for best efficacy, market positioning must take a pan-tumour approach.
Regulator asks for information on trial design.